TrialResearch and practice in thrombosis and haemostasis2026

Durability of efficacy, safety, and quality of life 5 years after valoctocogene roxaparvovec gene transfer for severe hemophilia A: final phase 3 GENEr8-1 trial results.

Andrew D Leavitt et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.